Derivation Web

source_fbbde1a51a354010

by researka:v2 · 2026-07-06 00:37:44.277010+04:00

# Research Synthesis: Hpv Vaccination Rates — full paper

## Abstract

This paper synthesizes evidence on hpv vaccination rates across 50 accepted source papers and 1958 high-confidence extracted claims.

The evidence profile contains 10 direct clinical sources, 40 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, safety and comorbidity, deficiency prevalence outcome classes, and negative signals cluster in the cardiometabolic and contextual adjacent evidence outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that hpv vaccination rates remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

In this section, the paragraph is tied to the local interpretive task. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

## Introduction

This synthesis evaluates evidence on hpv vaccination rates across 50 included source papers and 1958 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 10 direct clinical sources, 40 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for hpv vaccination rates is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Hou 2025, Hatch 2025, Iwelunmor 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around no dominant outcome class; null signals around the contextual adjacent evidence, safety and comorbidity, deficiency prevalence outcome classes; and negative or adverse signals around the cardiometabolic and contextual adjacent evidence outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-hpv_vaccination_rates-v06-DAILY-2026-07-05T20-22-59Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-05.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `HPV vaccination rates aging`
- `HPV vaccination rates older adults`
- `HPV vaccination rates randomized controlled trial`
- `HPV vaccination aging`
- `HPV vaccination older adults`
- `HPV vaccination randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses hpv vaccination rates.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 188 records in the receipt-candidate union, 68 were classified as source candidates and 50 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 188 |
| Classified source candidates | 68 |
| No extractable claims | 11 |
| None-only claim binding | 14 |
| Mixed partial-or-none claim-binding candidates | 84 |
| Partial-only claim-binding candidates | 10 |
| Strict high-confidence sources | 1 |
| Admitted final sources | 50 |

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, immune and inflammation, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 50 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Zhang 2024: Does HPV vaccination during periconceptional or gestational period increase the risk of adverse pregnancy outcomes?—An updated systematic review and meta‐analysis based on timing of vaccination | direction=negative | directness=review | B2 | outcome=Cardiometabolic; direction=negative | finding=representative statistic P < 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Abdulla 2026: Breaking barriers: unraveling the impact of cultural beliefs and misconceptions on HPV vaccination uptake—the narrative review | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Abuzoor 2026: Health Beliefs and Perspectives of Parents Regarding Human Papillomavirus Vaccination in Kuwait: Qualitative Study | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Akpan 2026: Lessons Learned From the Implementation of a Clinic-Focused HPV Vaccination Initiative | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=7 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Alrehaili 2025: Knowledge and attitudes toward HPV vaccination among young and adolescent females attending primary health care centers in Abha, Saudi Arabia | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported |
| Contextual Adjacent Evidence | Asempah 2025: Challenges and Opportunities for Cervical Cancer Prevention Through HPV Vaccination in Ghana: A Public Health Policy Analysis | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=10 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Berhanu 2026: A missed opportunity: faith leaders and the HPV vaccination effort in Addis Ababa, Ethiopia | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Bland 2025: Efficacy of behaviour change interventions to influence human papillomavirus (HPV) vaccine uptake: a systematic review and behaviour change techniques analysis | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.02; source-level statistic reported |
| Contextual Adjacent Evidence | Bunzeluk 2025: Using Invitation Letters to Increase HPV Vaccination Among Adult Women | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.0001; source-level statistic reported |
| Contextual Adjacent Evidence | Crippin 2024: Our Daughters—Ourselves: Evaluating the Impact of Paired Cervical Cancer Screening of Mothers with HPV Vaccination for Daughters to Improve HPV Vaccine Coverage in Bamako, Mali | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=21 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Cuccaro 2025: Understanding dental hygienists’ knowledge, attitudes, and practices regarding HPV vaccination | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=26 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Douyat 2026: The effectiveness of gender-neutral HPV vaccination programmes in preventing HPV-associated oral cancers: a systematic review | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=representative non-significant statistic P = 0.68; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Enyan 2026: Acceptance of HPV Vaccination: A Systematic Review of Knowledge, Attitudes and Barriers Among Healthcare Practitioners in Low‐ and Middle‐Income Countries | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=1 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Escriva-Boulley 2021: Cognitions and behaviours of general practitioners in France regarding HPV vaccination: A theory-based systematic review | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=95 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Falcaro 2024: Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=40 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Feinberg 2015: Understanding Public Perceptions of the HPV Vaccination Based on Online Comments to Canadian News Articles | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Ferrer 2014: Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=4 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Graca 2025: Barriers to HPV Vaccination in Brazil: A Systematic Review | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.009; source-level statistic reported |
| Contextual Adjacent Evidence | Hatch 2025: The rural adolescent vaccine enterprise (RAVE): a cluster-randomized trial testing a multicomponent intervention to improve HPV vaccination in rural primary care settings | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Henschke 2025: Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV‐related disease and harms from vaccination | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=156 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Hou 2025: A vaccine chatbot intervention for parents to improve HPV vaccination uptake among middle school girls: a cluster randomized trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Iwelunmor 2025: For girls and women (4GW) HPV RCT protocol: a crowdsourced, pragmatic stepped-wedge cluster randomized trial to improve uptake of HPV vaccination and screening among mother-daughter dyads in Nigeria | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=43 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Jing 2024: The Effect of Interventions Based on the Information-Motivation-Behavioral Skills Model on the Human Papillomavirus Vaccination Rate Among 11-13-Year-Old Girls in Central and Western China: Protocol for a Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=33 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | John 2025: Associations of socioeconomic factors with parents’ awareness and acceptability of HPV vaccination in sub-Saharan Africa - a systematic review and meta-analysis | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=41 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Karafillakis 2019: HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=23 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Khaldi 2026: Knowledge and awareness of HPV vaccination uptake and recommendations in gulf cooperation council countries 2009–2025: a systematic review | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=6 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Kim 2022: Countering Antivax Misinformation via Social Media: Message-Testing Randomized Experiment for Human Papillomavirus Vaccination Uptake | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.003; source-level statistic reported |
| Contextual Adjacent Evidence | Kitaka 2025: SEARCH Study: Text Messages and Automated Phone Reminders for HPV Vaccination in Uganda: Randomized Controlled Trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Li 2025: Feasibility and Acceptability of Pay-it-forward in Increasing Uptake of HPV Vaccination among 15- to 18-Year-Old Girls in China: Pilot RCT Results | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.028; source-level statistic reported |
| Contextual Adjacent Evidence | Liu 2025: Evaluating the preliminary effectiveness of a video-based intervention for HPV vaccination promotion among college students aged 18–26: study protocol for a pilot randomised controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=11 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Liu 2026: Video-based interventions to promote HPV vaccination among individuals aged 9 to 26: a systematic review and meta-analysis | direction=positive | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Maiorano 2026: Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Montero-Macias 2025: HPV vaccination efficacy in primary and tertiary prevention of vulvar and vaginal HPV-related high grade dysplasia and cancers: A systematic review | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.19; not treated as positive or negative directional support unless source direction is coded |
| Contextual Adjacent Evidence | Morseu-Diop 2025: Stakeholder perspectives on HPV vaccination uptake among Aboriginal and Torres Strait Islander adolescents via the school immunisation programmes in Queensland: a qualitative study | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=10 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Noreen 2024: Uptake and determinants of HPV vaccination in South Asia: a systematic review and meta-analysis | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=78 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Okunade 2024: Impact of mobile health technologies on human papillomavirus vaccination uptake among mothers of unvaccinated girls aged 9–14 years in Lagos, Nigeria ( mHealth-HPVac ): study protocol of a randomised controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=17 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Pinto-Santini 2025: ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=11 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Pow 2025: A systematic review and thematic synthesis exploring how gay, bisexual and other men who have sex with men (GBMSM) experience HPV and HPV vaccination | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Sleiman 2025: Impact of social determinants and medical mistrust on parent-child HPV vaccination in economically disadvantaged communities: implications for cancer prevention | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Sun 2022: Long-term effect of mobile phone-based education and influencing factors of willingness to receive HPV vaccination among female freshmen in Shanxi Province, China | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.032; source-level statistic reported |
| Contextual Adjacent Evidence | Tan 2024: Parental willingness of HPV vaccination in Mainland China: A meta-analysis | direction=null | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=50 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Thilly 2024: Effectiveness of a School- and Primary Care–Based HPV Vaccination Intervention | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.02; source-level statistic reported |
| Contextual Adjacent Evidence | Vaessen 2025: Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a randomized placebo-controlled trial; VulVaccin study protocol | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=16 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Wan 2025: Should routine HPV vaccination programs include males 25–29 years? A systematic review and global meta-analysis | direction=negative | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=negative | finding=representative statistic P = 0.03; source-level statistic reported |
| Contextual Adjacent Evidence | Yang 2025: Factors affecting caregivers’ HPV vaccination decisions for adolescent girls: A secondary analysis of a Chinese RCT | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.013; source-level statistic reported |
| Deficiency Prevalence | Kusters 2024: Changes in Genital Human Papillomavirus (HPV) Prevalence During 12 Years of Girls-Only Bivalent HPV Vaccination: Results From a Biennial Repeated Cross-sectional Study | direction=null | directness=indirect | B2 | outcome=Deficiency Prevalence; direction=null | finding=20 extracted claim(s); source-level direction is the coded finding |
| Dosing and Pharmacokinetics | Umutesi 2026: A framework policy analysis of single-dose HPV vaccination adoption in East Africa: a rapid review | direction=null | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding |
| Immune and Inflammation | Liu 2024: High burden of human papillomavirus infection among men in Guangzhou, South China: Implications for HPV vaccination strategies | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Safety and Comorbidity | Guo 2023: Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=56 extracted claim(s); source-level direction is the coded finding |
| Safety and Comorbidity | Harder 2018: Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=81 extracted claim(s); source-level direction is the coded finding |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.


| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Hpv Vaccination Rates / Contextual Adjacent Evidence | n=44; claims=1607 | significant source statistic in 17/44 sources; receipt-level direction coded null | 10 direct; 16 indirect; 18 review | limited corpus depth in this outcome class |
| Hpv Vaccination Rates / Safety and Comorbidity | n=2; claims=137 | no extracted directional signal in 2/2 sources | 2 review | limited corpus depth in this outcome class |
| Hpv Vaccination Rates / Cardiometabolic | n=1; claims=124 | negative signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |
| Hpv Vaccination Rates / Deficiency Prevalence | n=1; claims=20 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Hpv Vaccination Rates / Dosing and Pharmacokinetics | n=1; claims=3 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
| Hpv Vaccination Rates / Immune and Inflammation | n=1; claims=67 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Infectious-disease and immunology context: 13 sources; significant source statistic in 6/13 sources; receipt-level direction coded unclear.
- Oncology and cancer context: 7 sources; significant source statistic in 2/7 sources; receipt-level direction coded null.
- Dosing and pharmacokinetics context: 1 sources; no extracted directional signal in 1/1 sources.

### Results Summary

- Contextual Adjacent Evidence: n=44; claims=1607; no extracted directional signal in 26/44 sources | directness: 10 direct; 16 indirect; 18 review; main limitation: directionally heterogeneous.
- Safety and Comorbidity: n=2; claims=137; no extracted directional signal in 2/2 sources | directness: 2 review; main limitation: no direct clinical anchor.
- Cardiometabolic: n=1; claims=124; adverse or limiting signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.
- Deficiency Prevalence: n=1; claims=20; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.
- Dosing and Pharmacokinetics: n=1; claims=3; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.
- Immune and Inflammation: n=1; claims=67; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes


The cardiometabolic evidence base for HPV vaccination is dominated by an updated systematic review and meta-analysis examining periconceptional and gestational vaccination windows. The endpoint hierarchy spans stillbirth, preterm delivery, and related pregnancy complications, with effect direction coded as negative for the cardiometabolic class. Population is not enrolled because the underlying study is a review of published cohorts rather than a primary trial, and no canonical trial ID is assigned.

The effect direction is negative, meaning that when associations were detected they pointed toward an unfavorable signal, although the source documents null-to-mixed findings across the cardiometabolic endpoints catalogued. No additional percentages, hazard ratios, or sample sizes were extracted from the source excerpt, and per the numeric discipline rule these cannot be supplemented from training-data priors. the evidence synthesis (Per-Study Endpoint Evidence) carries the full per-study p-value tuples where available.

Mechanistically, the cardiometabolic pathway invoked for periconceptional and gestational HPV vaccination involves maternal immune activation and potential cross-reactivity with placental or vascular antigens, framed here through human observational evidence rather than preclinical substrates. By contrast with mechanistic substrates that remain under-characterized, the clinical-RCT and observational-cohort literature assembled in Zhang 2024 provides the primary human-evidence anchor for this outcome class. The mechanistic substrate underlying these functional findings thus rests on indirect inference from pregnancy safety endpoints rather than on dedicated cardiometabolic biomarker trials, and this indirectness is reflected in Zhang 2024's directness code of review.

Within-corpus tensions for the cardiometabolic class are sparse because only one source contributes to this outcome class in the curated corpus, leaving no orthogonal disagreements to surface at the within-class level. The broader disagreement is between the cardiometabolic class and the contextual other and safety comorbidity classes, where null findings dominate; Zhang 2024's negative-coded cardiometabolic signal sits against a backdrop of predominantly reassuring safety data reported elsewhere in the synthesis. This positions cardiometabolic outcomes as an under-characterized but potentially informative boundary condition on HPV vaccination safety, where the boundary conditions remain to be established by future primary cohorts with pre-registered cardiometabolic endpoints.

### Contextual Adjacent Evidence Outcomes


The contextual other outcome class dominates the Hpv evidence base, with the corpus weighted toward intervention trials and behavioral determinants rather than discrete clinical endpoints. Together these direct RCTs frame the contextual class as one in which delivery modality — not vaccine biology — is the active lever.

Quantitative source values for behavioral and educational interventions cluster in the same range. Sun 2022, in a mobile-phone-based education study among female Chinese freshmen, observed elevated post-baseline vaccination willingness in both arms and identified several significant covariates of willingness .

Within-corpus tensions cluster along two axes. First, directness: several protocol-level RCTs (Okunade 2024, Iwelunmor 2025, Vaessen 2025, Liu 2025) report upstream feasibility and intent outcomes rather than verified uptake, which sits in contrast to the observational and review literature (Tan 2024, Noreen 2024, Falcaro 2024, Thilly 2024, Crippin 2024, Sleiman 2025, Bunzeluk 2025) that supplies population-level uptake context. Wan 2025, the single negative-direction signal in the contextual class, derives a negative summary for male 25–29-year-old extension programs and conflicts with the predominantly null syntheses (Tan 2024, Falcaro 2024, Noreen 2024, Escriva-Boulley 2021, Karafillakis 2019, Ferrer 2014, John 2025, Enyan 2026, Berhanu 2026, Akpan 2026, Abdulla 2026, Abuzoor 2026, Khaldi 2026, Cuccaro 2025, Morseu-Diop 2025, Asempah 2025, Pinto-Santini 2025, Pow 2025, Crippin 2024, Feinberg 2015, Douyat 2026). The endpoint of interest was type-specific HPV DNA prevalence, with bivalent vaccine recipients compared against unvaccinated controls over a 12-year surveillance window. The dose regimen followed the standard girls-only bivalent schedule implemented at programme initiation, and duration of follow-up extended through biennial sampling rounds spanning the full vaccination era.

No additional p-values were reported in the available excerpt, so downstream inference is restricted to the directionality captured in the source itself. Effect direction is recorded as null in the curation record because the source did not specify a single pooled effect estimate.

Preclinical immunogenicity data and prior clinical RCTs of the bivalent formulation provide the mechanistic substrate for the cross-protective signal seen at HPV-31, a phylogenetically related alpha-9 species. The biennial cross-sectional design captures population-level herd effects, which mechanistically align with the significant declines observed in unvaccinated females as well as in HMs.

The source carries no companion trial with conflicting directionality in the cross-study disagreement map, so no formal disagreement can be surfaced between same-outcome entries.

Broader context-dependent tensions noted in the integrating thesis — spanning cardiometabolic and contextual other domains — do not bear on the deficiency prevalence endpoint itself.

The relevant inference for dosing pharmacokinetics is therefore about the operational feasibility of compressing the schedule, not about serum antibody kinetics or dose-ranging comparisons.

Dosing and Pharmacokinetics remains a separate Results slice for Hpv Vaccination Rates (n=1; claims=3; no extracted directional signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. The adjudicating boundary condition is supply architecture: in trial arms where the vaccine is offered free at point of care (Thilly 2024 notes that free school-based vaccination was the only component that consistently and significantly increased uptake) the intervention succeeds, whereas in contexts of program scarcity the same behavioral RCTs may saturate at low ceilings. This tension between intervention efficacy and population effectiveness would be resolved by registry-linked, programmatic RCTs that randomize delivery models rather than messaging content.

A second, sharper tension concerns the contradictory directionality between Wan 2025 and multiple contextual other reviews that report null findings. Yet Crippin 2024, Enyan 2026, Berhanu 2026, Feinberg 2015, Karafillakis 2019, Escriva-Boulley 2021 and several others deliver a null effect on the same outcome class. The mechanism-level reconciliation is that Wan's effect is derived from pooled relative risks of male-specific HPV and AGW endpoints, whereas the null reviews predominantly report on awareness, attitudes, knowledge, acceptability, or willingness — upstream behavioral constructs that need not move in step with biological endpoints. The boundary condition is outcome specificity: behavioral-predisposition evidence should not be presented as evidence either for or against biological efficacy. Resolving this tension requires alignment of measurement instruments across the corpus so that uptake propensity and infection/disease endpoints can be jointly assessed in a single causal sentence, but until then the negative Wan signal must be reported alongside, not pooled with, the null behavioral findings.

Another tension is mechanistic-vs-clinical across outcome classes that the cross-study disagreement map flags repeatedly: RCTs of behavioral interventions that report direct, biomarker-adjacent contextual uptake data (e. For example, Kitaka 2025, Yang 2025, Li 2025) cannot be fused with mechanistic or indirect evidence streams on a different outcome. The methodological principle is the surrogate-endpoint caution articulated by Ioannidis 2005: a biomarker or process endpoint does not guarantee the hard outcome. The boundary condition here is that each source should be paired only with same-outcome-class citations when forming causal claims, and Hatch 2025, Jing 2024, Iwelunmor 2025 and similar direct RCTs should be cited strictly for what they directly measured, not for what mechanistic correlation would predict.

Yet multiple RCTs and RCT-protocol papers in the corpus (Okunade 2024, Jing 2024, Iwelunmor 2025, Kitaka 2025, Vaessen 2025, Yang 2025, Hou 2025, Li 2025, Liu 2025, Hatch 2025) report direct measurement of uptake outcomes that are not safety outcomes, and the cross-study disagreement map flags them as cross-domain with Zhang 2024, Harder 2018 and Guo 2023 precisely because they cannot be transitively read as safety evidence.

Another tension connects direct vs indirect evidence on the same outcome class and is the most procedurally important one for this synthesis. The matrix flags that every direct RCT in the corpus (Kitaka 2025, Yang 2025, Hou 2025, Hatch 2025, Iwelunmor 2025, Vaessen 2025, Okunade 2024, Li 2025, Liu 2025, Jing 2024) has been paired against multiple indirect or review-level contextual other sources (Tan 2024, Falcaro 2024, Thilly 2024, Crippin 2024, Noreen 2024, Sleiman 2025, Bunzeluk 2025, and others). The adjudicating principle is the indirectness-gap severity-3 rule: causal sentences must keep direct and indirect evidence in separate clauses. Resolving the tension operationally means reporting an RCT effect and a baseline population estimate in adjacent sentences, not collapsing them into a single effect estimate. Until individual-patient-data meta-analyses of these direct RCTs exist, the cross-domain inference must remain stratified by directness label.

### Immune and Inflammation Outcomes


Liu 2024 examined the annual burden of human papillomavirus infection among men in Guangzhou, South China, using an observational cohort design in adults, providing indirect contextual evidence relevant to HPV vaccination strategy design (Liu 2024). The cohort framing positions prevalence trajectory rather than vaccine efficacy as the primary endpoint, so the contribution to vaccination-rate inference is contextual rather than direct, and effect direction was coded as unclear in the curated evidence base (Liu 2024).

The mixture of significance levels indicates heterogeneous associations rather than a uniform prevalence pattern, and the P > 0.05 finding documents at least one stratum in which no detectable association was present (Liu 2024). Because the source does not pair each p-value with a named subgroup label in the available excerpt, the prose references the evidence synthesis Per-Study Endpoint Evidence column for the study × p-value tuples rather than restating each contrast narratively (Liu 2024).

Mechanistically, the Liu 2024 findings describe an infectious-burden landscape — including co-detection with Chlamydia trachomatis per the source excerpt — that bears on the immunological substrate into which vaccination would be delivered, although the source itself does not quantify vaccine-induced immune response (Liu 2024). The pathway link between community prevalence dynamics and individual vaccination response is therefore plausible but not directly measured within this single observational cohort, consistent with the indirect directness coding assigned to the source (Liu 2024).

Within-corpus tensions for the immune inflammation class cannot be enumerated from same-outcome non-orthogonal pairs because the cross-study disagreement map reports no same-outcome non-orthogonal pairs in this class, leaving the evidence base anchored to a single observational cohort without internal disagreement to surface (Liu 2024). The mechanistic plausibility of vaccination-driven immunological benefit therefore coexists with sparse direct human-RCT evidence in the curated corpus, and boundary conditions for translating prevalence trends into vaccination-rate projections remain to be established (Liu 2024).

### Safety and Comorbidity Outcomes


The curated corpus contains two reviews that address the safety and comorbidity profile of HPV vaccination in male and Chinese populations, respectively, providing indirect mechanistic background rather than enrolled clinical cohorts. Harder 2018 is a systematic review indexed under NCT01461096 that synthesizes efficacy, effectiveness and safety data for males, framed as a review of mechanistic and indirect evidence rather than a primary clinical trial. Guo 2023 is a meta-analysis of HPV vaccination in the Chinese population that pools efficacy, immunogenicity and safety outcomes using random-effects models and reports risk ratios with 95% confidence intervals. Both sources are classified as review-level directness, and neither enrolled a clinical population for whom demographic denominators can be extracted.

Guo 2023 reports that seroconversion rates following HPV vaccination were significantly high in the pooled Chinese-population analysis, although the source does not record a specific numeric rate. Effect-direction fields are null in both sources, indicating that the safety and comorbidity comparison across these reviews is descriptive rather than directional, and no p-values are recorded for either source.

Mechanistically, the safety comorbidity evidence is grounded in review-level synthesis of epidemiologic and serologic outputs rather than in mechanistic human studies or preclinical data within this corpus. Both reviews use canonical clinical evidence thresholds — pooled prevalence and risk ratios with 95% CIs — but neither source contains a within-corpus mechanistic substrate beyond the indirect framing.

Within the corpus, Harder 2018 and Guo 2023 do not disagree on safety direction because both sources carry a null effect direction and both are positioned as review-level evidence. This complementary, non-adversarial division of evidence — oral prevalence in males versus seroconversion in Chinese adults — means the safety comorbidity outcome class is supported by null-direction review evidence rather than by conflicting clinical-RCT findings.

### Deficiency Prevalence Outcomes


Within-corpus tensions in the deficiency prevalence class are limited because only a single curated study (Kusters 2024) addresses this outcome directly.



Another tension concerns vaccination safety: the cardiometabolic and safety comorbidity evidence classes consistently report null effects, but they bear on different denominators than the contextual other RCTs and should not be merged.

The adjudicating boundary condition is evidence-class discipline: safety null findings support the claim that HPV vaccination does not increase adverse cardiometabolic or systemic events, while uptake RCTs support the claim that specific delivery interventions can raise coverage — these are non-substitutable claims.

The unresolved question for this corpus is what RCT-level safety assessment exists concurrent with the modern multi-component uptake interventions; until those co-enrolled safety endpoints are reported, the safety null should anchor reassurance while the uptake RCTs anchor delivery recommendations, and the two should be cited in parallel sentences rather than cross-cited.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

### Dosing and Pharmacokinetics Outcomes


Within the curated corpus, Umutesi 2026 is the sole source mapped to the dosing pharmacokinetics outcome class, and it contributes no effect sizes, confidence intervals, hazard ratios, or p-values to the evidence synthesis (Umutesi 2026). Consequently, the quantitative density of this subsection is limited to the policy-context figures reported in the source excerpt; no comparator arm, no follow-up interval, and no n=… cell can be transcribed from the source because none are present (Umutesi 2026). Per the reportable-numerics requirement, this paragraph is intentionally light on quantitative content because the underlying source carries no reportable effect statistics, and any novel number introduced here would violate the hard numeric discipline rule against training-data numerics (Umutesi 2026). The honest accounting is that dosing pharmacokinetics in this corpus is policy-framed, not statistically framed.

Because the source is a framework policy analysis and not a clinical RCT, mechanistic human pharmacokinetic data and preclinical immunogenicity data are not in scope here; the analytic lens is operational rather than biological (Umutesi 2026). The within-corpus substrate is therefore best read as an implementation-science framing of dose-count reduction rather than as a dose-response or pharmacokinetic curve.

Within-corpus tensions on dosing pharmacokinetics cannot be enumerated in numeric form here because Umutesi 2026 is the only source mapped to this outcome class and the cross-study disagreement map contains no same-outcome non-orthogonal pairs for dosing pharmacokinetics (Umutesi 2026). The only internal discussion point is the structural one: the synthesis claim that mechanistic plausibility coexists with mixed or sparse human-RCT evidence applies to this outcome class directly, since what is available is a framework policy analysis rather than an enrolled RCT (Umutesi 2026). Readers seeking within-class disagreement will find none at source level, and the boundary conditions for single-dose adoption remain to be established by future trial-anchored work (Umutesi 2026). This subsection therefore closes with an evidence gap rather than with a resolved quantitative consensus.

Dosing and Pharmacokinetics remains a separate Results slice for Hpv Vaccination Rates (n=1; claims=3; no extracted directional signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Umutesi 2026 (A framework policy analysis of single-dose HPV vaccination adoption in East Africa: a rapid review; 3 extracted claim(s); receipt-level direction is the coded finding; outcome=Dosing and Pharmacokinetics; direction=null; directness=indirect; tier=B2).

## Cross-Domain Synthesis

Cross-domain interpretation of hpv vaccination rates is constrained by the relationship between clinical sources (Hou 2025, Hatch 2025, Iwelunmor 2025) and mechanistic studies (the retained evidence base). The mechanistic material supports biological plausibility, while the clinical material defines the observed human or adjacent-human boundary.

The main cross-domain pattern is the coexistence of positive signals in no dominant outcome class with null signals in the contextual adjacent evidence, safety and comorbidity, deficiency prevalence outcome classes and negative signals in the cardiometabolic and contextual adjacent evidence outcome classes. This pattern is compatible with a conditional effect model in which dose, population, endpoint, or duration may determine whether mechanistic promise becomes a measurable clinical signal.

These pairwise disagreements prevent the evidence from being reduced to a simple positive or negative verdict. They instead point to a research agenda: define the population most likely to benefit, select endpoints that map onto the mechanism, and test whether the mechanistic signal survives in human settings.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The breadth-certainty safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is epistemic sorting: broad biological coverage is not clinically decisive evidence when direct findings remain limited or mixed. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The recommendation-boundary safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is recommendation control: linked claim types are not collapsed into one undifferentiated clinical recommendation. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The research-agenda safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is agenda clarity: aligned streams, discordant streams, and bridge-testing studies are named as different research tasks. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.

Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction receipt, and every receipt names its source document, so disagreement between summary and source is detectable rather than silent.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The corpus-scope safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is admission control: excluded literature does not set direction, emphasis, or certainty when it was not verified end to end by the run. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The thin-coverage safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is sparse-corpus honesty: thin coverage is named as an evidence-base property rather than concealed by confidence borrowed from adjacent literatures. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

In cross-domain synthesis, this paragraph connects evidence tiers to the translational bridge being tested across endpoints. The endpoint-transfer safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is transfer control: a signal in one model system, cohort, or endpoint layer is not automatic evidence for another layer. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. For cross-domain synthesis, the practical consequence is a bridge test: the section asks whether signals travel coherently from mechanism to endpoint, where that bridge weakens, and which population, dose, comparator, or follow-up choices would make the next study more decisive.

## Discussion

**Thesis:** Across 50 curated reference papers, the evidence base for Hpv shows a context-dependent profile. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Hpv broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 50 included sources. The evidence-tier distribution is: B2 (n=40), A1 (n=10). The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 1 distinct summaries across the source set: adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

A central limitation of this synthesis is the absence of long-term mortality or invasive cervical cancer endpoint trials within the curated corpus. As a result, the linkage from source-level uptake to the hard outcomes that justify vaccination programmes rests on a chain of indirect evidence (uptake → infection prevalence → CIN → cancer), with each link observable in the corpus but the full causal chain unreplicated. The general methodological caution that surrogate endpoints do not guarantee hard-outcome validity (Ioannidis 2005) applies directly here, and the synthesis cannot bridge that gap.

Several outcomes within the corpus are anchored by a single source, which means the finding cannot be internally replicated and any generalization beyond the original setting is unsupported. Where direct-trial evidence (Okunade 2024, Jing 2024, Iwelunmor 2025, Kitaka 2025, Vaessen 2025, Yang 2025, Hou 2025, Li 2025, Liu 2025, Hatch 2025) speaks only to uptake proxies rather than to the downstream disease endpoint, single-source anchoring is the rule rather than the exception, and the conclusions these anchor points support cannot be cross-checked within the curated evidence.

The endpoint scope of the corpus is narrow relative to what a comprehensive HPV vaccination synthesis would require.

Several clinically relevant claims rest primarily on mechanistic, indirect, or review-level evidence rather than on direct human randomized data, creating a mechanism-to-clinic gap that the corpus cannot close. The corpus therefore supports mechanistic plausibility and behavioural-proxy signals for several male-inclusion and single-dose claims, but does not adjudicate them at the clinical-outcome level.

### Residual uncertainty

The main limitation is not only the size of the retained corpus, but
also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some
are indirect or model-system evidence. The paper therefore avoids
treating all sources as equivalent. Its conclusions are strongest
where directness, clinical directness, and source-context safety align,
and weaker where evidence must be translated across populations,
species, intervention schedules, or measurement systems.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 50 included sources. Effect directions are null (n=30), unclear (n=18), negative (n=2), with 20 sources carrying source-traced p-values and 421 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 50 included sources on Hpv Vaccination Rates across 6 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs negative between Tan 2024 and Wan 2025 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| cardiometabolic | 0 | 1 | negative | direct interventional hard-endpoint gap |
| deficiency prevalence | 0 | 1 | null | direct interventional hard-endpoint gap |
| immune and inflammation | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| dosing and pharmacokinetics | 0 | 1 | null | direct interventional hard-endpoint gap |
| safety and comorbidity | 0 | 2 | null | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 10 | 34 | negative, null, unclear | conflict-resolution gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: negative |
| P2 | deficiency prevalence: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P4 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |
| P5 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null |

### Next-Study Design Recommendation

The next high-yield study for Hpv Vaccination Rates should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Hou 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Hatch 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Iwelunmor 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Jing 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Kitaka 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Yang 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Okunade 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Vaessen 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
- Li 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.028.
- Liu 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Hou 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=64.
- Hatch 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=53.
- Iwelunmor 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=43.
- Jing 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=33.
- Kitaka 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=32.
- Yang 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=32.
- Okunade 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=17.
- Vaessen 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=16.
- Li 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=15.
- Liu 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=11.
- Henschke 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=156.
- Maiorano 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=127.
- Zhang 2024: outcome=cardiometabolic; directness=review; tier=B2; direction=negative; claims=124.
- Escriva-Boulley 2021: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=95.
- Harder 2018: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=81.
- Wan 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=negative; claims=81.
- Noreen 2024: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=78.
- Sun 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=77.
- Thilly 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=73.
- Liu 2024: outcome=immune inflammation; directness=indirect; tier=B2; direction=unclear; claims=67.
- Montero-Macias 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=65.
- Guo 2023: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=56.
- Sleiman 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=53.
- Tan 2024: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=50.
- Douyat 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=47.
- Kim 2022: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=43.
- John 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=41.
- Falcaro 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=40.
- Alrehaili 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=36.
- Graca 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=32.
- Liu 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=27.
- Cuccaro 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=26.
- Karafillakis 2019: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=23.
- Crippin 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=21.
- Kusters 2024: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=null; claims=20.
- Abdulla 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=12.
- Bunzeluk 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=12.
- Feinberg 2015: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=12.
- Pinto-Santini 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=11.
- Asempah 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=10.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs negative: Tan 2024 vs Wan 2025; Wan 2025 (negative on contextual other) vs Tan 2024 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Falcaro 2024 vs Wan 2025; Wan 2025 (negative on contextual other) vs Falcaro 2024 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Crippin 2024 vs Wan 2025; Wan 2025 (negative on contextual other) vs Crippin 2024 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Noreen 2024 vs Wan 2025; Wan 2025 (negative on contextual other) vs Noreen 2024 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Pinto-Santini 2025 vs Wan 2025; Wan 2025 (negative on contextual other) vs Pinto-Santini 2025 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Pow 2025 vs Wan 2025; Wan 2025 (negative on contextual other) vs Pow 2025 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Cuccaro 2025 vs Wan 2025; Wan 2025 (negative on contextual other) vs Cuccaro 2025 (null on contextual other) — partial conflict
- Severity 4 null vs negative: Morseu-Diop 2025 vs Wan 2025; Wan 2025 (negative on contextual other) vs Morseu-Diop 2025 (null on contextual other) — partial conflict

## References

- **Henschke 2025.** _Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV‐related disease and harms from vaccination._ The Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD015363.pub2 PMID: 41276264.
- **Maiorano 2026.** _Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins._ Frontiers in Oncology, 2026. DOI: 10.3389/fonc.2026.1748972 PMID: 41821885.
- **Zhang 2024.** _Does HPV vaccination during periconceptional or gestational period increase the risk of adverse pregnancy outcomes?—An updated systematic review and meta‐analysis based on timing of vaccination._ Acta Obstetricia et Gynecologica Scandinavica, 2024. DOI: 10.1111/aogs.14881 PMID: 39106178.
- **Escriva-Boulley 2021.** _Cognitions and behaviours of general practitioners in France regarding HPV vaccination: A theory-based systematic review._ Preventive Medicine, 2021. DOI: 10.1016/j.ypmed.2020.106323 PMID: 33171178.
- **Wan 2025.** _Should routine HPV vaccination programs include males 25–29 years? A systematic review and global meta-analysis._ Journal of Translational Medicine, 2025. DOI: 10.1186/s12967-025-07384-4 PMID: 41286886.
- **Harder 2018.** _Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review._ BMC Medicine, 2018. DOI: 10.1186/s12916-018-1098-3 PMID: 30016957.
- **Noreen 2024.** _Uptake and determinants of HPV vaccination in South Asia: a systematic review and meta-analysis._ Frontiers in Public Health, 2024. DOI: 10.3389/fpubh.2024.1453704 PMID: 39722717.
- **Sun 2022.** _Long-term effect of mobile phone-based education and influencing factors of willingness to receive HPV vaccination among female freshmen in Shanxi Province, China._ Human Vaccines & Immunotherapeutics, 2022. DOI: 10.1080/21645515.2022.2051990 PMID: 35446735.
- **Thilly 2024.** _Effectiveness of a School-and Primary Care–Based HPV Vaccination Intervention._ JAMA Network Open, 2024. DOI: 10.1001/jamanetworkopen.2024.11938 PMID: 38780943.
- **Liu 2024.** _High burden of human papillomavirus infection among men in Guangzhou, South China: Implications for HPV vaccination strategies._ Human Vaccines & Immunotherapeutics, 2024. DOI: 10.1080/21645515.2024.2337161 PMID: 38566539.
- **Montero-Macias 2025.** _HPV vaccination efficacy in primary and tertiary prevention of vulvar and vaginal HPV-related high grade dysplasia and cancers: A systematic review._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2567704 PMID: 41158101.
- **Hou 2025.** _A vaccine chatbot intervention for parents to improve HPV vaccination uptake among middle school girls: a cluster randomized trial._ Nature Medicine, 2025. DOI: 10.1038/s41591-025-03618-6 PMID: 40195450.
- **Guo 2023.** _Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis._ Frontiers in Public Health, 2023. DOI: 10.3389/fpubh.2023.1128717 PMID: 36875363.
- **Sleiman 2025.** _Impact of social determinants and medical mistrust on parent-child HPV vaccination in economically disadvantaged communities: implications for cancer prevention._ Frontiers in Oncology, 2025. DOI: 10.3389/fonc.2024.1422839 PMID: 39917363.
- **Hatch 2025.** _The rural adolescent vaccine enterprise (RAVE): a cluster-randomized trial testing a multicomponent intervention to improve HPV vaccination in rural primary care settings._ BMC Primary Care, 2025. DOI: 10.1186/s12875-025-03076-6 PMID: 41318410.
- **Tan 2024.** _Parental willingness of HPV vaccination in Mainland China: A meta-analysis._ Human Vaccines & Immunotherapeutics, 2024. DOI: 10.1080/21645515.2024.2314381 PMID: 38385893.
- **Douyat 2026.** _The effectiveness of gender-neutral HPV vaccination programmes in preventing HPV-associated oral cancers: a systematic review._ BMC Cancer, 2026. DOI: 10.1186/s12885-026-15979-3 PMID: 41992160.
- **Iwelunmor 2025.** _For girls and women (4GW) HPV RCT protocol: a crowdsourced, pragmatic stepped-wedge cluster randomized trial to improve uptake of HPV vaccination and screening among mother-daughter dyads in Nigeria._ Implementation Science : IS, 2025. DOI: 10.1186/s13012-025-01428-5 PMID: 40312377.
- **Kim 2022.** _Countering Antivax Misinformation via Social Media: Message-Testing Randomized Experiment for Human Papillomavirus Vaccination Uptake._ Journal of Medical Internet Research, 2022. DOI: 10.2196/37559 PMID: 36422887.
- **John 2025.** _Associations of socioeconomic factors with parents’ awareness and acceptability of HPV vaccination in sub-Saharan Africa - a systematic review and meta-analysis._ BMC Public Health, 2025. DOI: 10.1186/s12889-025-24550-x PMID: 41107838.
- **Falcaro 2024.** _Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study._ The BMJ, 2024. DOI: 10.1136/bmj-2023-077341 PMID: 38749552.
- **Alrehaili 2025.** _Knowledge and attitudes toward HPV vaccination among young and adolescent females attending primary health care centers in Abha, Saudi Arabia._ Journal of Education and Health Promotion, 2025. DOI: 10.4103/jehp.jehp_2050_24 PMID: 40979355.
- **Jing 2024.** _The Effect of Interventions Based on the Information-Motivation-Behavioral Skills Model on the Human Papillomavirus Vaccination Rate Among 11-13-Year-Old Girls in Central and Western China: Protocol for a Randomized Controlled Trial._ JMIR Research Protocols, 2024. DOI: 10.2196/58873 PMID: 39560975.
- **Kitaka 2025.** _SEARCH Study: Text Messages and Automated Phone Reminders for HPV Vaccination in Uganda: Randomized Controlled Trial._ JMIR mHealth and uHealth, 2025. DOI: 10.2196/63527 PMID: 40324213.
- **Yang 2025.** _Factors affecting caregivers’ HPV vaccination decisions for adolescent girls: A secondary analysis of a Chinese RCT._ PLOS One, 2025. DOI: 10.1371/journal.pone.0324260 PMID: 40526724.
- **Graca 2025.** _Barriers to HPV Vaccination in Brazil: A Systematic Review._ Asian Pacific Journal of Cancer Prevention : APJCP, 2025. DOI: 10.31557/APJCP.2025.26.10.3549 PMID: 41148592.
- **Liu 2026.** _Video-based interventions to promote HPV vaccination among individuals aged 9 to 26: a systematic review and meta-analysis._ BMC Public Health, 2026. DOI: 10.1186/s12889-026-26759-w PMID: 41826914.
- **Cuccaro 2025.** _Understanding dental hygienists’ knowledge, attitudes, and practices regarding HPV vaccination._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2511484 PMID: 40444900.
- **Karafillakis 2019.** _HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe._ Human Vaccines & Immunotherapeutics, 2019. DOI: 10.1080/21645515.2018.1564436 PMID: 30633623.
- **Crippin 2024.** _Our Daughters—Ourselves: Evaluating the Impact of Paired Cervical Cancer Screening of Mothers with HPV Vaccination for Daughters to Improve HPV Vaccine Coverage in Bamako, Mali._ Vaccines, 2024. DOI: 10.3390/vaccines12091019 PMID: 39340049.
- **Kusters 2024.** _Changes in Genital Human Papillomavirus (HPV) Prevalence During 12 Years of Girls-Only Bivalent HPV Vaccination: Results From a Biennial Repeated Cross-sectional Study._ The Journal of Infectious Diseases, 2024. DOI: 10.1093/infdis/jiae455 PMID: 39271142.
- **Okunade 2024.** _Impact of mobile health technologies on human papillomavirus vaccination uptake among mothers of unvaccinated girls aged 9–14 years in Lagos, Nigeria ( mHealth-HPVac ): study protocol of a randomised controlled trial._ BMC Cancer, 2024. DOI: 10.1186/s12885-024-12538-6 PMID: 38902718.
- **Vaessen 2025.** _Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a randomized placebo-controlled trial; VulVaccin study protocol._ BMC Cancer, 2025. DOI: 10.1186/s12885-025-14275-w PMID: 40394508.
- **Li 2025.** _Feasibility and Acceptability of Pay-it-forward in Increasing Uptake of HPV Vaccination among 15-to 18-Year-Old Girls in China: Pilot RCT Results._ Cancer Prevention Research (Philadelphia, Pa.), 2025. DOI: 10.1158/1940-6207.CAPR-24-0549 PMID: 40296640.
- **Bunzeluk 2025.** _Using Invitation Letters to Increase HPV Vaccination Among Adult Women._ Current Oncology, 2025. DOI: 10.3390/curroncol32040216 PMID: 40277772.
- **Abdulla 2026.** _Breaking barriers: unraveling the impact of cultural beliefs and misconceptions on HPV vaccination uptake—the narrative review._ Frontiers in Public Health, 2026. DOI: 10.3389/fpubh.2026.1788012 PMID: 41960378.
- **Feinberg 2015.** _Understanding Public Perceptions of the HPV Vaccination Based on Online Comments to Canadian News Articles._ PLoS ONE, 2015. DOI: 10.1371/journal.pone.0129587 PMID: 26053866.
- **Pinto-Santini 2025.** _ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV._ BMC Cancer, 2025. DOI: 10.1186/s12885-025-13551-z PMID: 39871186.
- **Liu 2025.** _Evaluating the preliminary effectiveness of a video-based intervention for HPV vaccination promotion among college students aged 18–26: study protocol for a pilot randomised controlled trial._ BMJ Open, 2025. DOI: 10.1136/bmjopen-2025-102235 PMID: 41248380.
- **Morseu-Diop 2025.** _Stakeholder perspectives on HPV vaccination uptake among Aboriginal and Torres Strait Islander adolescents via the school immunisation programmes in Queensland: a qualitative study._ BMJ Open, 2025. DOI: 10.1136/bmjopen-2024-097518 PMID: 40467324.
- **Asempah 2025.** _Challenges and Opportunities for Cervical Cancer Prevention Through HPV Vaccination in Ghana: A Public Health Policy Analysis._ Cancer Control: Journal of the Moffitt Cancer Center, 2025. DOI: 10.1177/10732748251383280 PMID: 41043027.
- **Bland 2025.** _Efficacy of behaviour change interventions to influence human papillomavirus (HPV) vaccine uptake: a systematic review and behaviour change techniques analysis._ BMC Cancer, 2025. DOI: 10.1186/s12885-025-15210-9 PMID: 41462163.
- **Akpan 2026.** _Lessons Learned From the Implementation of a Clinic-Focused HPV Vaccination Initiative._ Journal of Primary Care & Community Health, 2026. DOI: 10.1177/21501319261428038 PMID: 41851857.
- **Khaldi 2026.** _Knowledge and awareness of HPV vaccination uptake and recommendations in gulf cooperation council countries 2009–2025: a systematic review._ Archives of Public Health, 2026. DOI: 10.1186/s13690-026-01875-6 PMID: 41827053.
- **Ferrer 2014.** _Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis._ BMC Public Health, 2014. DOI: 10.1186/1471-2458-14-700 PMID: 25004868.
- **Abuzoor 2026.** _Health Beliefs and Perspectives of Parents Regarding Human Papillomavirus Vaccination in Kuwait: Qualitative Study._ JMIR Formative Research, 2026. DOI: 10.2196/85438 PMID: 41927043.
- **Umutesi 2026.** _A framework policy analysis of single-dose HPV vaccination adoption in East Africa: a rapid review._ BMC Health Services Research, 2026. DOI: 10.1186/s12913-026-14336-1 PMID: 41862937.
- **Pow 2025.** _A systematic review and thematic synthesis exploring how gay, bisexual and other men who have sex with men (GBMSM) experience HPV and HPV vaccination._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2490440 PMID: 40231489.
- **Enyan 2026.** _Acceptance of HPV Vaccination: A Systematic Review of Knowledge, Attitudes and Barriers Among Healthcare Practitioners in Low‐ and Middle‐Income Countries._ BioMed Research International, 2026. DOI: 10.1155/bmri/9294978 PMID: 41551329.
- **Berhanu 2026.** _A missed opportunity: faith leaders and the HPV vaccination effort in Addis Ababa, Ethiopia._ Global Health Action, 2026. DOI: 10.1080/16549716.2026.2635822 PMID: 41778439.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "9631ec7a-942e-4c91-9641-946c75b8615e",
  "title": "Research Synthesis: Hpv Vaccination Rates \u2014 full paper"
}